General Usefulness of leronlimab
Post# of 148179
(Total Views: 995)
Posted On: 05/27/2020 7:45:42 PM
Howdy,
I am a retired physician with metastatic squamous cell carcinoma of the head and neck (SCCHN). I had the same thing about 20 years ago and if I had followed the recommendations of the director of head and neck surgery at Northwestern Medical School (my school
I would be dead right now.
My current situation is a little more complicated than it was 20 years ago, but for sure, any cytotoxic chemo is out of the question. The average survival with traditional treatment is about 6 months.
Surgery, radiation and immunotherapy are greatly preferred, but not at all standard.
I am writing, here, because immunotherapy sometimes doesn't work very well. Lots of people have looked at the problem and the most they can say is that it is complicated and has something to do with the micro-environment of the tumor. The consensus seems to be that a big part of the problem can be related to the presence of a localized cytokine storm in and around the tumor. The cytokines interfere with acquired immunity.
It this is true for (SCCHN), then it is probably true for a variety of refractory cancers.
When the Covid-19 excitement settles down. I think Cytodyn should write a broad request to the FDA, which would allow leronlimab to be used in any cases of end stage cancer.
To start the ball rolling, requesting the ability to provide emergency on a selective basis seems like it could help prime the pump.
By the way guys. It doesn't help CytoDyn to broadly criticize the FDA. If there is a specific issue or a specific person... have at it.
Some of the best people in the world are in the areas of biopharma and FDA regulation. Painting anyone with a broad brush is not right and you should not do it.
I am a retired physician with metastatic squamous cell carcinoma of the head and neck (SCCHN). I had the same thing about 20 years ago and if I had followed the recommendations of the director of head and neck surgery at Northwestern Medical School (my school
I would be dead right now. My current situation is a little more complicated than it was 20 years ago, but for sure, any cytotoxic chemo is out of the question. The average survival with traditional treatment is about 6 months.
Surgery, radiation and immunotherapy are greatly preferred, but not at all standard.
I am writing, here, because immunotherapy sometimes doesn't work very well. Lots of people have looked at the problem and the most they can say is that it is complicated and has something to do with the micro-environment of the tumor. The consensus seems to be that a big part of the problem can be related to the presence of a localized cytokine storm in and around the tumor. The cytokines interfere with acquired immunity.
It this is true for (SCCHN), then it is probably true for a variety of refractory cancers.
When the Covid-19 excitement settles down. I think Cytodyn should write a broad request to the FDA, which would allow leronlimab to be used in any cases of end stage cancer.
To start the ball rolling, requesting the ability to provide emergency on a selective basis seems like it could help prime the pump.
By the way guys. It doesn't help CytoDyn to broadly criticize the FDA. If there is a specific issue or a specific person... have at it.
Some of the best people in the world are in the areas of biopharma and FDA regulation. Painting anyone with a broad brush is not right and you should not do it.
(22)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼